TrialNet and DPT-1 Published Manuscripts - Rev. 02/17/17

1995


2000


2001


2002


7) * Diabetes Prevention Trial - Type 1 Diabetes Study Group. Effects of Insulin in Relatives of Patients with Type 1 Diabetes Mellitus. N Engl J Med 2002; 346(22):1685-91. PMID 12037147

2003


2004


Items with Asterisk* are all or in part DPT-1 Publications
Citations in bold have been added since last Steering Committee Meeting


2005


2006


2007


2008


31) Skysler JS, and the Type 1 Diabetes TrialNet Study Group. Update on Worldwide Efforts to Prevent Type 1 Diabetes. Ann N Y Acad Sci 2008; 1150:190-196. PMID 19120293, PMCID PMC2928677, NIHMS NIHMS250542


2009


Items with Asterisk * are all or in part DPT-1 Publications
Citations in bold have been added since last Steering Committee Meeting


37) * Triolo TM, Chase HP, Barker JM, for the DPT-1 Study Group. Diabetic subjects diagnosed through the Diabetes Prevention Trial-Type 1 (DPT-1) are often asymptomatic with normal A1C at diabetes onset. Diabetes Care 2009; 32:769-773. PMID 19407074, PMCID PMC2671125


2010

43) Bingley PJ, Matthews CL. Type 1 Diabetes TrialNet: Working Together to Prevent, Delay or Slow the Progression of Type 1 Diabetes. Pract Diab Int 2010; 27:98-99.

44) * Ferrannini E, Mari A, Nofrante V, Sosenko JM, Skyler JS, for the DPT-1 Study Group. Progression to Diabetes in Relatives of Patients with Type 1 Diabetes: Mechanisms and Mode of Onset. Diabetes 2010; 59(3):679-685. PMID 20028949, PMCID PMC2828663


Items with Asterisk* are all or in part DPT-1 Publications

Citations in bold have been added since last Steering Committee Meeting
Onset Type 1 Diabetes: A Randomised Double-Masked Controlled Trial. Lancet 2011; 378(9788):319-327. PMID 21714999, PMCID PMC3580128


60) * Sosenko JM, Skyler JS, Mahon J, Krischer JP, Beam CA, Boulware DC, Greenbaum CJ, Rafkin LE, Cowie C, Cuthbertson D, Palmer JP, the TrialNet and Diabetes Prevention Trial – Type 1 Study Groups. The Validation of the Diabetes Prevention Trial-Type 1 Risk Score and the Detection of Pre-Diabetes in the TrialNet Natural History Study. Diabetes Care 2011; 34(8):1785-1787. PMID 21680724, PMCID PMC3142063


65) * Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Cuthbertson D, Yu L, Schatz DA, Orban T, Eisenbarth G, Diabetes Prevention Trial-Type 1, and Type 1 Diabetes TrialNet Study Groups. A Longitudinal Study of GAD65 and ICA512 Autoantibodies during the Progression to Type 1 Diabetes in Diabetes Prevention Trial-Type 1 (DPT-1) Participants. (Brief Report) Diabetes Care 2011; 34(11):2435-2437. PMID 21911777, PMCID PMC3198298


2012

67) Yu L, Boulware DC, Beam CA, John CHutton JC, Wenzlau JM, Greenbaum CJ, Bingley PJ, Krischer JP, Sosenko JM, Skyler JS, Eisenbarth GS, Mahon JL, for the Type 1


69) * Sosenko JM, Skyler JS, Mahon J, Krischer JP, Beam CA, Boulware DC, Greenbaum CJ, Rafkin LE, Cowie C, Cuthbertson D, Palmer JP. The TrialNet and Diabetes Prevention Trial-Type 1 Study Groups. The Application of the Diabetes Prevention Trial Risk Score (DPTRS) for Identifying a Pre-Clinical State of Type 1 Diabetes. Diabetes Care 2012; 35(7):1552-1555. PMID 22547092, PMCID PMC3379597


75) Alkanani AK, Rewers M, Waugh K, Barriga K, Gottlieb PA, Zipris D. Dysregulated Toll-like Receptor-induced Interleukin-1B and Interleukin-6 Responses in Subjects at Risk for the Development of Type 1 Diabetes. Diabetes 2012; 61(10):2525-2533. PMID 22751696, PMCID PMC3447890


2013


83) Krisher JP, the Type 1 Diabetes TrialNet Study Group. The Use of Intermediate Endpoints in the Design of Type 1 Diabetes Prevention Trials. Diabetologia 2013; 56(9):1919-1924. PMID 23744306, PMCID PMC3743228

84) * Sosenko JM, Skyler JS, Palmer JP, Krisher JP, Yu L, Mahon J, Beam CA, Boulware DC, Rafkin L, Schatz D, Eisenbarth G, the Type 1 Diabetes TrialNet, and the Diabetes Prevention Trial-Type 1 Study Groups. The Prediction of Type 1 Diabetes by Multiple Autoantibody Levels and Their Incorporation into an Autoantibody Risk Score in Relatives of Type 1 Diabetes Patients. Diabetes Care 2013; 36(9):2615-2620. PMID 23818528, PMCID PMC 3747899


88) Weinberg A, Boulware D, Dighero B, Orban T, for the Type 1 Diabetes Abatacept Study Team. Effect of Abatacept on Immunogenicity of Vaccines in Individuals with Type 1 Diabetes. Vaccine 2013; 31(42):4791-4794. PMID 23962535, PMCID PMC3803163

89) * Sosenko JM, Skyler JS, Beam CA, Krischer JP, Greenbaum CJ, Mahon J, Rafkin LE, Matheson D, Herold KC, Palmer JP, and the Type 1 Diabetes TrialNet and the Diabetes Prevention Trial-Type 1 Study Groups. Acceleration of the Loss of the First-Phase Insulin Response during the Progression to Type 1 Diabetes in Diabetes Prevention Trial-Type 1 Participants. Diabetes 2013; 62(12):4179-4183. PMID 23863814, PMCID PMC3837047


2014

91) Creusot RJ, Trucco M, Clare-Salzler MJ, Fathman CG. It's Time to Bring Dendritic Cell Therapy to Type 1 Diabetes. Diabetes 2014; 63(1):20-30. Published TrialNet and DPT-1 Related Manuscript PMID 24357690, PMCID PMC3968436


94) Sosenko JM, Skyler JS, Mahon J, Krischer JP, Greenbaum CJ, Rafkin LE, Beam CA, Boulware DC, Matheson D, Cuthbertson D, Herold KC, Eisenbarth G, Palmer JP; the Diabetes Type 1 TrialNet, and Diabetes Prevention Trial-Type 1 Study Groups. Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for Improving the Accuracy of the Risk Classification of Type 1 Diabetes. Diabetes Care 2014; 37(4):979-984. PMID 24550217, PMCID PMC3964487


100) Orban T, Beam CA, Xu P, Moore K, Jiang Q, Deng J, Muller S, Gottlieb P, Spain L, Peakman M, and the Type 1 Diabetes TrialNet Abatacept Study Group. Reduction in CD4 Central Memory T-cell subset in Co-Stimulation Modulator Abatacept-Treated Patients with Recent-Onset Type 1 Diabetes is Associated with Slower C-Peptide Decline. Diabetes 2014; 63(10):3449-3457. PMID 24834977, PMCID PMC4171657


2015


109) Sosenko JM, Skyler JS, Beam CA, Boullware D, Mahon JL, Krischer JP, Greenbaum CJ, Rafkin LE, Matheson D, Herold KC, Palmer JP, The Diabetes Type 1 TrialNet, and
Diabetes Prevention Trial-Type 1 Study Groups. The Development and Utility of a Novel Scale that Quantifies the Glycemic Progression toward Type 1 Diabetes over Six Months. Diabetes Care 2015; 38(5):940-942. PMID 25758770, PMCID PMC4407750


112) Chase HP, Boullware D, Rodriguez H, Donaldson D, Chritton S, Rafkin-Mervis L, Krischer J, Skyler JS, Clare-Salzler M, Type 1 Diabetes TrialNet Nutritional Intervention to Prevent (NIP) Type 1 Diabetes Study Group. Effect of Docosahexaenoic Acid (DHA) Supplementation on Inflammatory Cytokine Levels in Infants at High Genetic Risk of Type 1 Diabetes. Pediatric Diabetes 2015; 16(4):271-9. 7/12/14 Epub ahead of print. PMID 25039804, PMCID PMC4291300

113) * Sosenko JM, Skyler JS, Palmer JP, The Diabetes Type 1 TrialNet, and Diabetes Prevention Trial-Type 1 Study Groups. The Development, Validation, and Utility of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS). Curr Diab Rep 2015; 15(8):626. PMID 26077017, PMCID PMC4795007


2016


121) Bingley P, Boulware D, Krischer JP, for the Type 1 Diabetes TrialNet Study Group. The Implications of Autoantibodies to a Single Islet Antigen in Relatives with Normal Glucose Tolerance: Development of Other autoantibodies and Progression to Diabetes.. Diabetologia 2016; 59(3):542-549. Dec 16 Epub ahead of print, Accepted November 3, 2015 PMID 26676824, PMCID PMC4742489


125) Moya R, Robertson HK, Payne D, Narasale A, Koziol J., the Type 1 Diabetes TrialNet Study Group, and Davies JD. A Pilot Study Showing Associations Between Frequency of CD4+ Memory Cell Subsets at Diagnosis and Duration of Partial Remission in Type 1 Diabetes. Clinical Immunology 2016; 166:72-80. (PMC available 5/1/17), 2016; April 22 Epub ahead of print Accepted 4/21/16. PMID 27114212, PMCID PMC4902740


Between Body Mass Index and Insulin Resistance and Type 1 Diabetes Among TrialNet Pathway to Prevention Participants. Diabetologia 2016; 59(6):1186-1195. (PMC available 6/1/17), 2016 Mar 19 Epub ahead of print, Accepted March 2016 PMID 26995649, PMCID PMC5081287


130) Narsale A, Moya R, Robertson HK, the Type 1 Diabetes TrialNet Study Group, and Davies JD. Data on Correlations Between T Cell Subset Frequencies and Length of Partial Remission in Type 1 Diabetes. Data in Brief 2016; 8:1348-1351. Accepted as a Data in Brief with the manuscript entitled "A Pilot Study Showing Associations Between Frequency of CD4+ Memory Cell Subsets at Diagnosis and Duration of Partial Remission in Type 1 Diabetes". Old title: Immune Cell Subsets Frequencies in Patients Newly Diagnosed with Type 1 Diabetes. PMID 27579340, PMCID PMC4992037

131) * Sosenko JM. Staging the Progression to Type 1 Diabetes with Prediagnostic Markers. Curr Opin Endocrinol Diabetes Obes 2016; 23(4):297-305. (PMC available 8/1/17). Review Article PMID 27362539, PMCID PMC4936493


133) Hao W, Gitelman S, DiMeglio LA, Boulware D, Greenbaum CJ, for the Type 1 Diabetes TrialNet Study Group. Fall in C-Peptide During First 4 Years from Diagnosis of Type 1 Diabetes: Variable Relation to Age, HbA1c and Insulin Dose. Diabetes Care 2016; 39(10):1664-1670. (PMC available 10/1/17) 2016 July 15 Epub ahead of print, Diabetes Care Accepted 6/15/16. PMID 27422577, PMCID PMC5033079


136) Bundy B, Krischer JP, Type 1 Diabetes TrialNet Study Group. A Model Based Approach to Sample Size Estimation in Recent Onset Type 1 Diabetes. Diabetes
Citations in bold have been added since last Steering Committee Meeting.

2017


140) Sosenko JM, Yu L, Skyler JS, Krischer JP, Gottlieb PA, Bouware D, Miao D, Palmer JP, Steck AK, the Type 1 Diabetes TrialNet Study Group. The Use of Electrochemiluminescence (ECL) Assays to Predict Autoantibody and Glycemic Progression Toward Type 1 Diabetes in Individuals with Single Autoantibodies. Diabetes Technol Ther 2017. 2017 Feb 8 Epub ahead of print, Accepted 1/5/17. PMID 2817779, PMCID PMC as supplied by publisher